Video guest: Josephine Mwangi

October 2017
25 26 27 28 29 30 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5



Follow the CTA Brussels Daily


twitter logo


facebook logo cta

Monday, 03 December 2012

EU-WHO anti-malaria project in Africa

The EU and the World Health Organisation (WHO) carried out a project aimed at developing national regulatory frameworks for anti-malaria medicine quality in six African countries.
The EU Project "Working with African countries to ensure a pharmaceutical quality response to malaria" was implemented in Cameroon, Ethiopia, Ghana, Kenya, Nigeria and Tanzania, and had as main purpose to develop technical specifications and professional guidance on the basis of which National Regulatory Authorities (NRAs) could asses and ensure the quality of anti malaria medicine present on the market.
According to a study conducted in 2003 in the six target countries by the WHO more than 50% of the anti-malaria medicine did not respond basic quality requirements. At the end of the project in 2012 the total medicine failure rate dropped to 28,5%. The largest rate of failure was registered in Cameroon (with more than 60% rate of failure among tested medicine), while the smallest was registered in Ethiopia (with 0% failure rate).  
Among the most important actions included in the project were: training regulators regarding quality requirements, providing technical specifications for labs developing anti-malaria medicines, providing support for manufacturers, inspecting sites and ingredients, and training health-professionals to monitor and report adverse drug reactions.
It is estimated that in 2010 there were 216 million cases of malaria, resulting in 655,000 deaths. 81% of these cases and 91% of deaths happened in Africa.

Source: CTA Brussels